Product Pipeline

Liposomal Grb-2

Bio-Path’s lead product candidate, BP-100-1.01 (Liposomal Grb-2), has completed six cohorts of a Phase I study for hematological cancers, including Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML) , Acute Lymphoblastic Leukemia (ALL) and Myelodysplastic Syndrome (MDS) .

Grb-2 (Growth factor Receptor Bound protein-2) is an adaptor protein that links tyrosine kinases such as bcr-abl with their downstream signaling molecules, including MAPK and AKT, which are critical regulators of cancer proliferation and survival. Liposomal Grb-2 seeks to suppress the function or expression of Grb-2, interrupt the vital signaling function and have a therapeutic effect. 

The Company is preparing to start a Phase II program, which will include three Phase II clinical trials of Liposomal Grb-2 salvage therapy in combination with frontline therapy. It is anticipated that the first of these trials will evaluate Liposomal Grb-2 as a combination therapy in Acute Myeloid Leukemia (AML).